27 results
8-K
EX-99.2
IOBT
IO Biotech Inc
13 Nov 23
IO Biotech Announces 2023 Third Quarter Results
8:10am
responsibility at Gilead Sciences, most recently as Program and Clinical Lead for Gilead’s GS-5829 (BET inhibitor) and GS-4059 (BTK inhibitor
8-K
EX-99.2
3v04opw3oro03o
7 Aug 23
IO Biotech, Inc. Announces $75 Million Private Placement Financing
8:31am
8-K
EX-10.1
zothwdk
7 Aug 23
IO Biotech, Inc. Announces $75 Million Private Placement Financing
8:31am
8-K
EX-99.1
4c80pg7 vr5bwtg
18 Jul 23
IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer
4:05pm
PRE 14A
ytrittw16zdq0lnb
14 Apr 23
Preliminary proxy
4:39pm
8-K
hmac1pf6lt7 6yrm
13 Oct 22
IO Biotech Announces Appointment of New Chief Financial Officer
4:05pm
8-K
EX-99.1
qqp7phby7l20lck
13 Oct 22
IO Biotech Announces Appointment of New Chief Financial Officer
4:05pm
DEF 14A
5ff4kqymet
14 Apr 22
Definitive proxy
4:02pm
10-K
1o9twg
31 Mar 22
Annual report
5:07pm
8-K
EX-10.1
1rb0ysbi53 b8k49
6 Dec 21
Entry into a Material Definitive Agreement
9:00am
424B4
w8ehogrg yf
8 Nov 21
Prospectus supplement with pricing info
5:20pm